Patients with single-hit TP53-mutated chronic lymphocytic leukemia (CLL) should be considered a high-risk genetic subgroup, similar to those with multi-hit TP53 mutations, according to new research.
Although data on the significance of TP53 status exist, research is conflicting on the clinical, pathogenetic, and prognostic profiles of CLLs with single-hit or multi-hit TP53 mutations.
Hamza Tariq, MD, of Northwestern Memorial Hospital, Chicago, Illinois, led a team of researchers who retrospectively investigated the allele status of TP53 in patients at their institution from January 2019 to May 2024.